A kind of medicine for preventing and treating restenosis and its preparation and use method

Abstract

The invention discloses a medicine for preventing and curing restenosis and a preparation method and a using method thereof. The effective components of the medicine include guaianese squiterpenes compounds P1, P2 and P3, wherein P1 is Zedoalactone B; P2 is a stereoisomer of P1; P3 is Zedoarondiol; and the effective components are extracted from Curcum lump powder by water bath, ultrafiltration separation, nanofiltration concentration, chromatographic purity analysis and nuclear magnetic resonance structure comparison. The using method of the medicine is to coat a carrying device with the medicine taking the compounds P1, P2 and P3 as the effective components. The medicine can prevent and cure restenosis, and compared with a conventional sirolimus-eluting stent, the medicine can inhibit the proliferation of vascular smooth muscle cells and inflammatory responses of vascular walls. Besides, the medicine can promote healing of vascular endothelial cells, avoids long-term thrombotic complications; and the dose is low, the cost is low and toxic or side effects are avoided.

Description

technical field [0001] The invention relates to the field of extracts of traditional Chinese medicines, in particular to a medicine for preventing and treating restenosis with guaiac-type sesquiterpene compounds as active ingredients, a method for preparing the medicine with zedoary and a method for using the medicine. Background technique [0002] At present, percutaneous coronary intervention (PCI) is the main method for the treatment of coronary heart disease, but the main defect of this method is postoperative restenosis at the site of stenting. Intravascular thrombosis, elastic recoil, arterial remodeling, neointimal hyperplasia, smooth muscle hyperplasia, vascular remodeling and inflammation are the main factors leading to restenosis. [0003] In order to solve the problem of restenosis, in recent years, traditional stents are commonly coated with drugs to inhibit the occurrence of restenosis. Significant progress has been made in restenosis, but because these drugs c...

AI Technical Summary

Problems solved by technology

[0003] In order to solve the problem of restenosis, in recent years, traditional stents are commonly coated with drugs to inhibit the occurrence of restenosis. Significant progress has been made in restenosis, but because these drugs can inhibit the healing of the damaged intima after balloon dilation, long-term thrombotic complications have increased significantly. It will increase the incidence of death or myocardial infarction (in-stent thrombosis), and the long-term prognosis is not better than that of the previous bare metal stent. The incidence of heart disease after interventional treatment of acute myocardial infarction is about 20% per year, and the use of western drug-coated stents The incidence of restenosis is still around 10%

In addition, drug-coated stents are expensive, and an imported stent is about 20,000 yuan, which is not suitable for the promotion and development of my country's national conditions, which greatly increases medical costs and the economic burden of patients

[0004] Aiming at the pathophysiological mechanism of restenosis, drugs with antithrombotic, anti-inflammatory, anti-cell migration and proliferation effects should have the effect of preventing restenosis in theory, but the research results of systemic application of these drugs after PCI are disappointing. Disappointed, not only the effect of reducing restenosis is limited, the key is that some of these drugs have serious toxic effects and side effects

Images